TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6283753
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg isopenbutolol (pure R‐form)
Study: 25079477
Drug: Mg alginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg alginate plus simethicone
Study: 21700623
Drug: Single-dose oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oseltamivir in morbidly obese patients
Study: 21700623
Drug: Single-dose oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oseltamivir in control (non-obese) subjects
Study: 21700623
Drug: Single-dose oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oseltamivir carboxylate in morbidly obese patients
Study: 21700623
Drug: Single-dose oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oseltamivir carboxylate in control (non-obese) subjects
Study: 16739183
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment model (TTM)
Study: 15520323
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg PO
Study: 8098243
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg once-daily nebivolol
Study: 8098243
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg once-daily nebivolol
Study: 8098243
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg once-daily atenolol
Study: 8098243
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg once-daily atenolol
Study: 3632148
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal with prebound aspirin
Study: 1360699
Drug: Wheat fibre
Normalized name: triticum (wheat fibre)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat fibre (16 g day-1)
Study: 1360699
Drug: Ispaghula (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ispaghula (16 g day-1)
Study: 6145726
Drug: Diazepam (15.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (15.8 mg)
Study: 29402522
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/rosuvastatin 20 mg
Study: 29402522
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/rosuvastatin 5 mg
Study: 26965765
Drug: Low carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carbohydrate diet (75 g per day)
Study: 16170182
Drug: Dacarbazine 250
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine 250 mg/m2 and cisplatin 30 mg/m2 combined with interferon‐alfa‐2b 10 x 10(6) U/m2 (arm A)
Study: 16170182
Drug: Dacarbazine 250
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine 250 mg/m2 and cisplatin 30 mg/m2 combined with interferon‐alfa‐2b 10 x 10(6) U/m2 and IL-2 (arm B)
Study: 11994348
Drug: Weekly injections
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly injections of testosterone (100 mg/wk)
Study: 19667501
Drug: SSRIs (e.g.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (e.g., paroxetine, citalopram)
Study: 84260
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of vitamin C given daily for 28 days
Study: 24783926
Drug: Five-element music
Normalized name: HISTA-FIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-element music therapy
Study: 2544249
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy and Dactinomycin (Actinomycin D) + Vincristine + Adriamycin +/− Cyclophosphamide
Study: 580761
Drug: Rifampicin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (oral dose, specific dosage not mentioned)
Study: 580761
Drug: Increasing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing oral dose of rifampicin
Study: 580761
Drug: Rifampicin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (oral dosage forms of the same nominal strength)
Study: 31981713
Drug: High-dose rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose rifapentine with moxifloxacin for four months
Study: 31981713
Drug: High-dose rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose rifapentine without moxifloxacin for four months
Study: 31981713
Drug: Conventional six-month
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional six-month treatment regimen
Study: 23240909
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of AS03‐adjuvanted A/California/7/2009 (H1N1) vaccine
Study: 23240909
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of AS03‐adjuvanted A/California/7/2009 (H1N1) vaccine
Study: 20860765
Drug: Informed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informed therapy (group A)
Study: 19531054
Drug: Repaglinide/metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide/metformin FDC BID
Study: 19531054
Drug: Repaglinide/metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide/metformin FDC TID
Study: 17327813
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (titrated doses)
Study: 7529155
Drug: Plasma, serum,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma, serum, or immunoglobulin preparations from donors
Study: 23481666
Drug: Chemokine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemokine and cytokine responses of peripheral blood mononuclear cells stimulated with TLR2, 4, or 7/8 agonists
Study: 17206703
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg infliximab (IFX)
Study: 17206703
Drug: 3-dose IFX
Normalized name: IFX-1
DrugBank: Vilobelimab (DB16416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose IFX induction at weeks 0, 2, and 6
Study: 17206703
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) for acute steroid-refractory colitis
Study: 11238498
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (80-microg patches) + oral norethisterone (1 mg daily)
Study: 9755259
Drug: xylitol syrup
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: xylitol syrup
Study: 9755259
Drug: xylitol lozenge
Normalized name: xylitol Lozenge Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: xylitol lozenge
Study: 9755259
Drug: control syrup
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: control syrup
Study: 9755259
Drug: control lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: control lozenge
Study: 3245292
Drug: Concentrated human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated human diploid cell vaccine (HDCV) with human rabies immune globulin (HRIG)
Study: 3245292
Drug: Concentrated and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated and purified human diploid cell vaccine (HDCV) with human rabies immune globulin (HRIG)
Study: 25151541
Drug: Natural oil-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural oil-based emulsion containing allantoin (cream 1)
Study: 25151541
Drug: Aqueous cream
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous cream (cream 2)
Study: 20033409
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (10 mg/kg/die for 3 days, then 2.5 mg/kg/die)
Study: 20033409
Drug: Standard-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose methylprednisolone (1 mg/kg/die for 3 days, then 2.5 mg/kg/die)
Study: 20033409
Drug: Standard-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose methylprednisolone
Study: 15679716
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (BUD) 800 mug daily for 3 months
Study: 10336792
Drug: Alprazolam (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0, 0.25, 0.50, 0.75 mg)
Study: 27578365
Drug: Esketamine (Ketanest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine (Ketanest S®) administered intravenously during a 55 min resting-state fMRI scan
Study: 22987083
Drug: Patupilone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patupilone (10 mg/m² intravenously every 3 weeks)
Study: 22987083
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) (50 mg/m² intravenously every 4 weeks)
Study: 21246846
Drug: Abdominal acupuncture
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal acupuncture plus Long's bone-setting manipulation (combined therapy)
Study: 12887127
Drug: HRT (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (0.625 mg of conjugated equine estrogen combined with 2.5 mg of medroxyprogesterone acetate) for 12 months in HT-HRT group
Study: 12887127
Drug: HRT (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (0.625 mg of conjugated equine estrogen combined with 2.5 mg of medroxyprogesterone acetate) for 12 months in NT-HRT group
Study: 10365610
Drug: Mivacurium (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium (0.25 mg/kg; 3 x SD95)
Study: 8370422
Drug: NOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOP regimen (mitoxantrone 16 mg/m2, vincristine 2 mg, prednisolone 250 mg day 1-4 and 17-20)
Study: 8370422
Drug: M+P regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: M+P regimen (melphalan 0.25 mg/kg and prednisolone 100-200 mg/day day 1-4)
Study: 31823654
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with nivolumab
Study: 31823654
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with nivolumab and linrodostat mesylate
Study: 19895770
Drug: Increased therapist
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased therapist structure during aftercare treatment
Study: 15767638
Drug: High-dose cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide, cisplatin, and carmustine (HD-CPB) with stem-cell support
Study: 15767638
Drug: Intermediate-dose cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose cyclophosphamide, cisplatin, and carmustine (ID-CPB) with G-CSF support
Study: 15383197
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg levofloxacin
Study: 9559801
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g levofloxacin
Study: 8963007
Drug: Dimethyl ether-propane
Normalized name: DIMETHYL ETHER/PROPANE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethyl ether-propane cryogenic spray (DMEP)
Study: 1858160
Drug: OKT3 for
Normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 for the first 14 days after OLT with low-dose steroids
Study: 1858160
Drug: Cyclosporine, steroids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine, steroids, and azathioprine
Study: 6133803
Drug: Timiperone (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timiperone (1.0 mg/tablet, daily dose of 1-3 tablets for the first day, up to 12 tablets for 12 weeks)
Study: 6133803
Drug: Haloperidol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (1.5 mg/tablet, daily dose of 1-3 tablets for the first day, up to 12 tablets for 12 weeks)
Study: 30101824
Drug: Etilefrine 2
Normalized name: etilefrine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etilefrine 2 mg
Study: 22527894
Drug: Hyaluronan-enriched transfer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan-enriched transfer medium (HETM) (0.5 mg/ml hyaluronan)
Study: 19172627
Drug: Dex‐P (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dex‐P (4 mg/ml) continuously applied for 14 days via a round window catheter
Study: 19172627
Drug: Dex‐P (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dex‐P (4 mg/ml) after 3 months follow-up
Study: 19172627
Drug: Dex‐P (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dex‐P (4 mg/ml)
Study: 12420185
Drug: Tinnitus Retraining
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinnitus Retraining Therapy combined with cognitive behavioral group therapy
Study: 12420185
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral group therapy alone
Study: 7917733
Drug: Preoperative multimodal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative multimodal analgesia regimen (morphine 0.15 mg kg‐1 i.m., perphenazine 0.03 mg kg‐1 i.m., indomethacin 100 mg rectal suppository)
Study: 7917733
Drug: Placebo (midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (midazolam 0.05 mg kg‐1 i.m. and placebo rectal suppository)
Study: 1632399
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (treatment and placebo)
Study: 2060256
Drug: Ibuprofen 100
Normalized name: ibuprofen 100 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 100 mg + Caffeine 100 mg
Study: 2060256
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg + Caffeine 100 mg
Study: 6297368
Drug: Melphalan treatment
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan treatment for mucinous tumours in Stages Ia and Ib
Study: 6297368
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Melphalan and radiotherapy
Study: 6297368
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment for well differentiated, early mucinous tumours in Stage Ia
Study: 6297368
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment for poorly differentiated tumours in Stages I and II
Study: 11981600
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg methadone
Study: 11981600
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg methadone
Study: 8124803
Drug: Dipyridamole echocardiography
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole echocardiography (0.84 mg/kg over 10 hours)
Study: 5472756
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin in a therapeutic dosage
Study: 31271554
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (3 g/day for 12 weeks)
Study: 23980090
Drug: Brivanib 800
Normalized name: Brivanib
DrugBank: Brivanib (DB11958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib 800 mg orally once per day plus best supportive care (BSC)
Study: 20881867
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering treatments
Study: 12782900
Drug: Stepped-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care treatment (counseling and nicotine patch therapy)
Study: 12782900
Drug: Minimal intervention
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal intervention (no additional treatment)
Study: 7901058
Drug: Tinidazole 2
Normalized name: tinidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 2 g administered 12 hours before surgery
Study: 2419945
Drug: iloprost (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: iloprost (3 infusions of 5 hours each)
Study: 31990685
Drug: MIC treatment
Normalized name: Humatrix Microclysmic Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIC treatment
Study: 24928796
Drug: Oxybutynin 10
Normalized name: oxyBUTYnin 10% transdermal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 10 mg
Study: 20937671
Drug: Rituximab 2×1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 2×1000 mg + MTX
Study: 20937671
Drug: Rituximab 2×500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 2×500 mg + MTX
Study: 18591315
Drug: L-isoleucine
Normalized name: L-Isoleucine
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-isoleucine
Study: 18591315
Drug: L-isoleucine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-isoleucine and L-valine
Study: 18591315
Drug: L-valine
Normalized name: L-valine
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-valine
Study: 18591315
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of L-isoleucine and L-valine
Study: 15042546
Drug: Low AGE
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low AGE diet (L-AGE)
Study: 10518249
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) 200 mg/I.M. weekly for six months
Study: 7488444
Drug: Alteplase (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (100 mg over three hours)
Study: 1785705
Drug: 2.5 ml
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml of a 0.5% bupivacaine solution
Study: 1785705
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of a 0.125% bupivacaine solution in normal saline
Study: 6920253
Drug: Pereflat (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pereflat (3 tablets daily for 3 days)
Study: 6920253
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 tablets daily for 3 days)
Study: 30591959
Drug: Vaccine alone
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine alone (arm B)
Study: 30591959
Drug: Vaccine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine plus all-trans-retinoic acid (arm C)
Study: 26112091
Drug: docetaxel, cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel, cisplatin and 5‐fluorouracil induction chemotherapy followed by carboplatin concurrent chemoradiotherapy
Study: 26112091
Drug: conventional concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional concurrent chemoradiotherapy
Study: 20603439
Drug: Neoadjuvant cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant cisplatin-based chemotherapy
Study: 19710081
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of xylitol (from toothpaste studies)
Study: 18318099
Drug: Conventional physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physiotherapy and regular medications
Study: 1978212
Drug: Sulphasalazine (less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine (less than or equal to 3 g/day)
Study: 226841
Drug: Premarin tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin tablets, 1.25 mg per day for 3 weeks
Study: 19487381
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule
Study: 19487381
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (IFN‐alpha) 9 MU subcutaneously thrice weekly
Study: 15272670
Drug: Initial solutions
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial solutions based on minimization/maximization of dose to critical structures and targets
Study: 11384628
Drug: Low-isoflavone diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-isoflavone diet (8 mg/day)
Study: 11384628
Drug: High-isoflavone diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-isoflavone diet (65 mg/day)
Study: 11384628
Drug: High-isoflavone diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-isoflavone diet (130 mg/day)
Study: 8995343
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (1000 mg/day) for 4 weeks
Study: 8425703
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon alfa therapy for chronic hepatitis C
Study: 3300755
Drug: Midazolam 15
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 15 mg orally followed at 35 min by i.v. saline
Study: 28606084
Drug: Cinnamon (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon (6 capsules, 3 g daily)
Study: 28606084
Drug: Wheat flour
Normalized name: Wheat Flour
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat flour (6 capsules, 2.5 g daily)
Study: 23683393
Drug: Short-stretch bandages
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-stretch bandages applied weekly for 2 weeks, followed by a class II elastic stocking for 2 weeks (group A)
Study: 15894775
Drug: N-acetylcysteine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 600 mg orally twice daily for two days
Study: 10765098
Drug: RPLND +
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPLND + 2 cycles of chemotherapy (arm A)